About the Program

In 2002, Bayer HealthCare instituted the Bayer Hemophilia Awards Program with the following mission:

The Bayer Hemophilia Awards Program supports basic and clinical research and education in hemophilia. Through grants provided to early career investigators, fellows in training, and other hemophilia care professionals, the program seeks to support the next steps for the next generation of care and treatment options for people with hemophilia worldwide.

Who We Are

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG, with annual sales of EUR 16,913 million (2010), is one of the world’s leading, innovative companies in the health care and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 53,400 employees and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

Bayer envisions the Hemophilia Awards Program as a step toward making the dream of hemophilia cures and improved treatments a reality.

The Bayer Hemophilia Awards Program demonstrates our commitment to the global bleeding disorders community and to advancing the state of the art of hemophilia care.

Research Priorities

Currently, the Program’s Research Priorities are focused on hemophilia. The program’s research priorities for the 2013/2014 cycle are as follows:

  • Research into prophylaxis regimens for hemophilia patients, including the generation of outcomes data and measures of adherence.
  • Research into the impact of advancing age on hemophilia patients, including the effect of co-morbidities previously unseen in the hemophilia patient population.
  • Projects evaluating how to prevent inhibitor development.
  • Clinical studies focusing on treatment modalities for hemophilia.
  • Research focused on understanding the therapeutic mechanism of action of FVIIa
  • Innovations that would lead to improved safety, efficacy or duration of action of rFVIIa for the treatment of hemophilia
  • Development of experimental in vitro and in vivo models to evaluate therapeutics for the treatment of bleeding disorders
  • Discovery or development of new recombinant molecules with potential therapeutic value in bleeding disorders, including those with a longer duration of action
  • New delivery options for these molecules, including gene therapy
  • Research to define a molecular basis for inhibitor development in hemophilia
  • Health outcomes and quality-of-life research related to hemophilia
  • Studies designed to increase the diagnosis, recognition and treatment of hemophilia in underserved areas.

Previous Research

In previous award cycles the Program has provided funding to support several projects in the following areas:

  • Aspects of the molecular biology of vWF structure and function and the diagnosis and treatment of vWD
  • The function and regulation of platelets and the diagnosis of platelet disorders.

As a result, the Program will not award projects in these areas during this award cycle.

Excluded Research Topics

In order to maintain a focus on hemophilia and bleeding disorders, the Program will not support research focused on:

  • Products or technologies licensed or patented by competitors of Bayer
  • Cancer diagnosis or therapy
  • AIDS diagnosis or hepatitis therapy except where specifically related to patients with hemophilia and HIV, HCV or HBV
  • Cardiovascular disease diagnosis or therapy
  • Purely thrombotic disorders.

Dates & Deadlines

Thank you for your interest in applying for the Bayer Hemophilia Awards Program. This program represents Bayer’s continuing commitment to taking the next steps for the next generation of people with hemophilia to enjoy a better quality of life and treatment options.

Applications will be processed solely through the Internet and all applications must be submitted in English.

As a first step, applicants should submit a Letter of Intent describing the proposed project in 500 words or fewer. All Letters of Intent submitted will receive an e-mail confirming receipt.

Letters of Intent (LOI) will be reviewed by all 12 members of the Grants Review and Awards Committee. In some cases, additional information may be requested.

Selected applicants will be invited to submit a full proposal that will be reviewed by at least two members of the Grants Review and Awards Committee. These applicants will be e-mailed a full application form.

The results of the review process and funding decisions will be communicated to applicants in May each year. Funded applicants must send a letter of acceptance and enter into an agreement outlining obligations and understandings prior to disbursement of funds.

Awardees will be invited to attend an Awards Dinner that will coincide with the bi-annual meetings of the World Federation of Hemophilia (WFH) or the International Society for Thrombosis and Hemostasis (ISTH).

The table below summarizes the application timelines for 2013/14.

Action Date
LOI submissions Permitted throughout year
Deadline for consideration November 30, 2013
GRAC reviews LOIs December 2013/January 2014
GRAC informs applicants January 15, 2014
Applicants develop proposals January/February 2014
Full Proposals submitted March 1, 2014
GRAC reviews Full Proposals March 2014
Applicants notified of GRAC decisions April 1, 2014
Funding available WFH Mid-May

Application Process

Letters of Intent and Full Applications are reviewed by the Grants Review and Awards Committee which comprises 12 members, representing many of the leading experts from clinical and academic medicine:

  • Johannes Oldenburg MD, Bonn, Germany (chairman)
  • Marijke van den Berg MD, Utrecht, Netherlands
  • Erik Berntorp MD, Malmö, Sweden
  • Craig Kessler MD, Washington DC, USA
  • David Lillicrap MD, Kingston, Canada
  • Pier Mannucci MD, Milan, Italy
  • Andrea Pritchard Kennedy, PhD, RN, MN, Calgary, AB, Canada
  • Brenda Riske MS, MBA, MPA, Aurora, CO, USA
  • Midori Shima MD, Nara, Japan
  • Alok Srivastava MD, Vellore, India
  • Alison Street MD, Melbourne, Australia
  • Gil White MD, Milwaukee, WI, USA

All members of the Grants Review and Awards Committee will review the Letters of Intent and determine which candidates will be invited to submit full applications. Full applications will be reviewed by at least two members of the committee.

Reviewers will evaluate full applications according to the criteria outlined in the Awards section of this website. The reviewers will provide written comments and preliminary numeric scores according to these criteria.

The Committee will meet to discuss individual proposals including strengths, weaknesses and scoring. In this meeting, a consensus score for each grant application will be agreed upon. Proposals will then be ranked according to these scores in order to determine funding. In the event of identical scoring, the Committee will discuss the proposals in question and revise the scoring in order to clearly define a ranked priority. Funding will occur on a regional basis.

Three regions are defined as:

  1. United States and Canada
  2. Europe (for the purposes of this award, the Europe region includes Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom)
  3. Japan, China, India, Australia and all other countries.

Awards will be determined on the final priority score as agreed by the Grants Review and Awards Committee. In the event that inadequate numbers of acceptable applications are received from a particular region, additional acceptable proposals will be funded solely on the basis of priority scores, without regard to region.

The Committee’s decision is final and there is no appeal mechanism. Applicants who have constructive suggestions about the review of their applications, or the process in general, are encouraged to contact us. See Contact.

Conflict of Interest

The Program has ‘conflict of interest’ guidelines that ensure reviews are conducted in a fair and equitable manner. Reviewers will not participate in the review or priority scoring of applications in which they, or institutions with which they are affiliated, have an interest. Also, to the extent practicable, reviewers will not participate in the review of proposals competing for funding with proposals for individuals associated with their institutions.

Confidentiality

The members of the Grants Review and Awards Committee are bound by the confidentiality rules generally applicable to such bodies.

Current Award Recipients: 2013

Fellowship Project Award

Samantha Gouw Samantha Gouw
Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands
Genetic markers of inhibitor development
Mara Malerba Mara Malerba
Fondazione Luigi Villa, Milan, Italy
Burden of osteoporosis study
Grace Monis Grace Monis
University of Washington Medical Center, Seattle, WA, USA
Stem cell therapy for hemophilia
Bobby Duc Tran Bobby Duc Tran
Emory University, Atlanta, GA, USA
Association of adherence to factor replacement therapy with health literacy and numeracy

Early Career Investigator Award

Roger Preston Roger Preston
Trinity College Dublin, Ireland
The role of glycoprotein Ibα in mediating FVIIa therapeutic activity
Federico Mingozzi Federico Mingozzi
Université Pierre et Marie Curie, Paris, France
Novel strategies to circumvent preexisting humoral immunity to AAV vectors
Nikolett Wohner Nikolett Wohner
INSERM, Paris, France
Clearance mechanisms of native and modified activated factor VII
David Markusic David Markusic
University of Florida, FL, USA
Overcoming imunological barriers to AAV gene therapy for hemophilia

Special Project Award

Carl Blobel Carl Blobel
Hospital for Special Surgery, New York, NY, USA
Role of the iRhom2/TACE/TNFα signaling axis in hemophilic arthropathy
Paris Margaritis Paris Margaritis
The Children’s Hospital of Philadelphia, PA, USA
Novel role of the endothelium in the hemostatic action of FVIIa administration in hemophilia
Anne Angelillo-Scherrer Anne Angelillo-Scherrer
University Medical Center and University of Lausanne, Switzerland
Blocking protein S to treat hemophilia in mice
Keiji Nogami Keiji Nogami
Nara Medical University, Kashihara, Japan
A novel regulatory mechanism of factor (F)VIIa/tissue factor associated with FVIII on the initial phase of coagulation

Caregiver Award

Elena Boccalandro Elena Boccalandro
Fondazione Luigi Villa, Milan, Italy
Aging with hemophilia
Cathliyn Buranahirun Cathliyn Buranahirun
Children’s Hospital Los Angeles, CA, USA
Multicultural needs assessment and transition to adult care for adolescent hemophilia patients
Cesar Haddad Cesar Haddad
Lebanese Association For Hemophilia, Beirut, Lebanon
Optimal physiotherapy treatment for Lebanese persons with hemophilia, based on objective measurements
Luz Villalaz Luz Villalaz
Hospital Del Niño, Republica De Panama
Clinics for young people with hemophilia; providing them with valuable tools for the future

Past Award Recipients